Patient Stratification

CellPrint scientists are using the CellPrint™ platform to develop important insights about pathogenesis and to advance the discovery and development of novel therapies. Patient stratification, the identification of groups of patients sharing characteristics of cell-specific molecular expression, is a key element of these efforts.

An example of the use of CellPrint™ to stratify patients is a study of ZAP70 expression in patients with chronic lymphocytic leukemia (CLL). ZAP70 expression level had been shown to be related to patient survival but the lack of a definitive threshold using standard flow cytometry degraded the value of ZAP70 as a prognostic biomarker.

Sensitivity of ZAP70 expression with CellPrint™ exceeded the sensitivity of standard flow cytometry by more than 10-fold. As shown in the figure below, the distribution of expression with standard flow cytometry did not show any features that would suggest meaningful stratification (left panel) but with CellPrint™ the distribution of expression clearly indicated two distinct patient groups (right panel). The stratification revealed by CellPrint™ was significant in that the leukemic cells segregated by the trough in ZAP70 expression showed distinct differences in a variety intermolecular relationships and overall molecular organization.

Example of Superior Patient Stratification with CellPrint™ versus Standard Flow Cytometrystratification2

Notes
• Results are from a CellPrint study of ZAP70 expression using CD19+ cells from 79 persons diagnosed with chronic lymphocytic leukemia (CLL).
• ZAP70 is a kinase in the antigen receptor signaling pathway.
• Study was organized by the Eastern Cooperative Oncology Group.


 In addition to differences in molecular organization, the two groups of CLL patients showed distinct differences in clinical outcomes. Patients with ZAP70 expression on the left side of the trough lived longer than patients with expression levels on the right side. These findings highlight the value that CellPrint™ can provide to resolve important differences in patient groups and help optimize therapeutic approaches.

Example Showing Differences in Clinical Outcomes in Patient Groups Resolved with CellPrint™survival2

Notes
• Results are from a CellPrint study of ZAP70 expression using CD19+ cells from 79 persons diagnosed with chronic lymphocytic leukemia (CLL).
• ZAP70 is a kinase in the antigen receptor signaling pathway.
• Study was organized by the Eastern Cooperative Oncology Group.
• For the log-rank test comparing survival distributions, p = 0.003 for overall survival and p < 0.001 for progress-free survival.